Tirzepatide side effects and safety context

Tirzepatide's most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, dyspepsia, decreased appetite, and abdominal pain, each reported in at least 5% of treated patients — and its labeling carries a boxed warning about thyroid C-cell tumors seen in rodent studies (Mounjaro label, DailyMed). Because it is an approved drug tested in thousands of trial participants, this profile is far better characterized than that of almost any other compound covered on this site — which cuts both ways: the risks are real, but they are known, quantified, and managed within a prescribing framework.

GI symptoms follow directly from the mechanism: GLP-1 receptor activation slows gastric emptying and suppresses appetite. In SURMOUNT-1 (n=2,539), the most common adverse events were gastrointestinal, mostly mild to moderate, and concentrated during the dose-escalation period (Jastreboff et al., NEJM 2022). This timing is why the labels build in a slow, stepped titration — see the dosing education page.

The Zepbound label's ≥5% list is somewhat longer than Mounjaro's, adding injection-site reactions, fatigue, hypersensitivity reactions, belching, hair loss, and gastroesophageal reflux disease (Zepbound label, DailyMed). Hair loss deserves a note: it is generally attributed to rapid weight loss itself (telogen effluvium) rather than a direct drug effect, and it appears on the label because it occurred more often than with placebo.

Tirzepatide caused thyroid C-cell tumors in rats at clinically relevant exposures. Whether this translates to humans — including medullary thyroid carcinoma (MTC) — is unknown, but the consequence is concrete: tirzepatide is contraindicated in anyone with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2, and patients are counselled to report symptoms such as a neck mass, difficulty swallowing, or persistent hoarseness (Mounjaro label). This warning is shared across the incretin class, including semaglutide. A prescriber screens for this family history before starting the drug — a step that self-directed use skips entirely.

Beyond the boxed warning, the labeling flags several less common but serious risks:

• Acute pancreatitis — treatment is discontinued if it is suspected.
• Gallbladder disease — gallstones and cholecystitis occur more often, a known accompaniment of rapid weight loss.
• Hypoglycemia — primarily when tirzepatide is combined with insulin or sulfonylureas, which often need dose reductions.
• Acute kidney injury — usually secondary to volume depletion from severe vomiting or diarrhea, not direct kidney toxicity.
• Diabetic retinopathy worsening — in patients with pre-existing retinopathy (Mounjaro label).
• Delayed gastric emptying — can change how oral medications absorb, and has driven anesthesia guidance about incretin drugs before planned procedures.
• Hypersensitivity reactions — including rare serious ones.

Both labels also note these risks are managed through monitoring and individualized decisions — the infrastructure that comes with a prescription (Zepbound label).

Vials sold as "research use only" tirzepatide add a second layer of risk on top of the drug's own pharmacology:

• Purity, actual peptide content, and sterility are unverified — a vial labeled 10 mg may contain more, less, or something else.
• Dosing depends on manual reconstitution math, a recurring source of large overdoses with incretin peptides.
• No one screens for the MTC/MEN 2 contraindication, drug interactions, or pregnancy (the labels note weight-loss drugs offer no benefit and potential harm in pregnancy).
• Warning-level events — pancreatitis pain, dehydration, persistent vomiting — may go unrecognised without clinical follow-up.

The honest framing: the approved product's side-effect profile is well understood and actively managed in practice; gray-market material carries the same pharmacological risks plus unknown ones, with none of the management. For what the drug does when it works as intended, see the benefits page; for the broader class question, see are GLP-1 peptides safe long-term.